Pharmacoeconomics of continuous versus intermittent infusion of piperacillin-tazobactam for the treatment of complicated intraabdominal infection.
DeRyke
C Andrew
CA
Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT 06102, USA.
Kuti
Joseph L
JL
Mansfield
Debra
D
Dana
Adrian
A
Nicolau
David P
DP
D000005:Abdomen / Q000503:physiopathology*; D000328:Adult; D001424:Bacterial Infections / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous / Q000379:methods*; D008297:Male; D008875:Middle Aged; D010397:Penicillanic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000191:economics; D010878:Piperacillin / Q000008:administration & dosage / Q000191:economics*; D000078142:Tazobactam
D010397:Penicillanic Acid; D000078142:Tazobactam; D010878:Piperacillin